Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model.

Orecchia P, Balza E, Pietra G, Conte R, Bizzarri N, Ferrero S, Mingari MC, Carnemolla B.

Cancers (Basel). 2019 Aug 23;11(9). pii: E1232. doi: 10.3390/cancers11091232.

2.

Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.

Mortara L, Balza E, Bruno A, Poggi A, Orecchia P, Carnemolla B.

Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018. Review.

3.

Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

Balza E, Carnemolla B, Orecchia P, Rubartelli A, Poggi A, Mortara L.

Curr Med Chem. 2018 Sep 4. doi: 10.2174/0929867325666180904121118. [Epub ahead of print]

PMID:
30182839
4.

Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.

Orecchia P, Conte R, Balza E, Pietra G, Mingari MC, Carnemolla B.

Oncotarget. 2015 Nov 10;6(35):37426-42. doi: 10.18632/oncotarget.6055.

5.

Periostin is a novel therapeutic target that predicts and regulates glioma malignancy.

Mikheev AM, Mikheeva SA, Trister AD, Tokita MJ, Emerson SN, Parada CA, Born DE, Carnemolla B, Frankel S, Kim DH, Oxford RG, Kosai Y, Tozer-Fink KR, Manning TC, Silber JR, Rostomily RC.

Neuro Oncol. 2015 Mar;17(3):372-82. doi: 10.1093/neuonc/nou161. Epub 2014 Aug 19.

6.

Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.

Mortara L, Orecchia P, Castellani P, Borsi L, Carnemolla B, Balza E.

Cancer Med. 2013 Aug;2(4):478-87. doi: 10.1002/cam4.89. Epub 2013 May 29.

7.

A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma.

Orecchia P, Conte R, Balza E, Petretto A, Mauri P, Mingari MC, Carnemolla B.

Eur J Cancer. 2013 May;49(8):2022-33. doi: 10.1016/j.ejca.2012.12.019. Epub 2013 Jan 24.

PMID:
23352437
8.

Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.

Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, Fry CD, White ES, Sisson TH, Tayob N, Carnemolla B, Orecchia P, Flaherty KR, Hershenson MB, Murray S, Martinez FJ, Moore BB; COMET Investigators.

Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-56. doi: 10.1152/ajplung.00139.2012. Epub 2012 Oct 5.

9.

Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.

Ventura E, Balza E, Borsi L, Tutolo G, Carnemolla B, Castellani P, Zardi L.

BMC Biotechnol. 2011 Nov 10;11:104. doi: 10.1186/1472-6750-11-104.

10.

Identification of a novel cell binding site of periostin involved in tumour growth.

Orecchia P, Conte R, Balza E, Castellani P, Borsi L, Zardi L, Mingari MC, Carnemolla B.

Eur J Cancer. 2011 Sep;47(14):2221-9. doi: 10.1016/j.ejca.2011.04.026. Epub 2011 May 24.

PMID:
21605971
11.

Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.

Ventura E, Sassi F, Parodi A, Balza E, Borsi L, Castellani P, Carnemolla B, Zardi L.

PLoS One. 2010 Feb 10;5(2):e9145. doi: 10.1371/journal.pone.0009145.

12.

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L.

Int J Cancer. 2010 Jul 1;127(1):101-10. doi: 10.1002/ijc.25018.

13.

Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins.

Ventura E, Sassi F, Fossati S, Parodi A, Blalock W, Balza E, Castellani P, Borsi L, Carnemolla B, Zardi L.

J Biol Chem. 2009 Sep 25;284(39):26646-54. doi: 10.1074/jbc.M109.025924. Epub 2009 Jul 24.

14.

A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B.

Balza E, Sassi F, Ventura E, Parodi A, Fossati S, Blalock W, Carnemolla B, Castellani P, Zardi L, Borsi L.

Int J Cancer. 2009 Aug 15;125(4):751-8. doi: 10.1002/ijc.24473. Erratum in: Int J Cancer. 2009 Nov 15;125(10):2487.

15.

Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins.

Barboro P, D'Arrigo C, Repaci E, Bagnasco L, Orecchia P, Carnemolla B, Patrone E, Balbi C.

Exp Cell Res. 2009 Jan 15;315(2):226-39. doi: 10.1016/j.yexcr.2008.10.017. Epub 2008 Oct 28.

PMID:
19000672
16.

Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.

Barboro P, Rubagotti A, Orecchia P, Spina B, Truini M, Repaci E, Carmignani G, Romagnoli A, Introini C, Boccardo F, Carnemolla B, Balbi C.

Cell Oncol. 2008;30(1):13-26.

17.

Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein.

Avignolo C, Bagnasco L, Biasotti B, Melchiori A, Tomati V, Bauer I, Salis A, Chiossone L, Mingari MC, Orecchia P, Carnemolla B, Neri D, Zardi L, Parodi S.

FASEB J. 2008 Apr;22(4):1237-45. Epub 2007 Nov 29.

PMID:
18048579
18.

Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.

Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L.

Eur J Immunol. 2007 Dec;37(12):3381-92.

19.

Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.

Castriconi R, Dondero A, Negri F, Bellora F, Nozza P, Carnemolla B, Raso A, Moretta L, Moretta A, Bottino C.

Eur J Immunol. 2007 Nov;37(11):3190-6.

20.

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.

Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L.

Clin Cancer Res. 2006 Apr 15;12(8):2575-82.

21.

Nuclear matrix protein expression in prostate cancer: possible prognostic and diagnostic applications.

Barboro P, Rubagotti A, Boccardo F, Carnemolla B, Darrigo C, Patrone E, Balbi C.

Anticancer Res. 2005 Nov-Dec;25(6B):3999-4004. Review.

22.

Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome.

Musante L, Candiano G, Bruschi M, Santucci L, Carnemolla B, Orecchia P, Giampuzzi M, Zennaro C, Sanna-Cherchi S, Carraro M, Oleggini R, Camussi G, Perfumo F, Ghiggeri GM.

Clin Exp Immunol. 2005 Sep;141(3):491-9.

23.

Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc.

Nieddu E, Melchiori A, Pescarolo MP, Bagnasco L, Biasotti B, Licheri B, Malacarne D, Tortolina L, Castagnino N, Pasa S, Cimoli G, Avignolo C, Ponassi R, Balbi C, Patrone E, D'arrigo C, Barboro P, Vasile F, Orecchia P, Carnemolla B, Damonte G, Millo E, Palomba D, Fassina G, Mazzei M, Parodi S.

FASEB J. 2005 Apr;19(6):632-4. Epub 2005 Jan 25.

PMID:
15671156
24.

PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.

Pende D, Bottino C, Castriconi R, Cantoni C, Marcenaro S, Rivera P, Spaggiari GM, Dondero A, Carnemolla B, Reymond N, Mingari MC, Lopez M, Moretta L, Moretta A.

Mol Immunol. 2005 Feb;42(4):463-9.

PMID:
15607800
25.

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.

Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, Negri F, Conte R, Corrias MV, Moretta L, Moretta A, Bottino C.

Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5. Epub 2004 Aug 16.

26.

Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis.

Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG.

Electrophoresis. 2004 May;25(9):1327-33.

PMID:
15174055
27.

Selective targeted delivery of TNFalpha to tumor blood vessels.

Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L.

Blood. 2003 Dec 15;102(13):4384-92. Epub 2003 Aug 21.

28.

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A.

J Exp Med. 2003 Aug 18;198(4):557-67. Epub 2003 Aug 11.

29.

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L.

Am J Pathol. 2002 Nov;161(5):1695-700.

30.

Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin.

Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L.

Int J Cancer. 2002 Nov 1;102(1):75-85.

31.

Use of human recombinant antibodies to the marker of angiogenesis ed-b in cancer therapy.

Borsi L, Carnemolla B, Neri D, Zardi L.

Tumori. 2001 Nov-Dec;87(6):S8-10. Review. No abstract available.

PMID:
11989617
32.

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L.

Blood. 2002 Mar 1;99(5):1659-65.

33.

Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody.

Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L.

Am J Pathol. 1999 May;154(5):1345-52.

35.

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D.

J Biol Chem. 1998 Aug 21;273(34):21769-76.

36.

Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.

Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G.

Nat Biotechnol. 1997 Nov;15(12):1271-5.

PMID:
9359110
37.

Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4beta1 and alpha4beta7 integrins.

Moyano JV, Carnemolla B, Domínguez-Jiménez C, García-Gila M, Albar JP, Sánchez-Aparicio P, Leprini A, Querzé G, Zardi L, Garcia-Pardo A.

J Biol Chem. 1997 Oct 3;272(40):24832-6.

38.

Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.

Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L.

Int J Cancer. 1996 Nov 4;68(3):397-405.

39.

Human tenascin-R. Complete primary structure, pre-mRNA alternative splicing and gene localization on chromosome 1q23-q24.

Carnemolla B, Leprini A, Borsi L, Querzé G, Urbini S, Zardi L.

J Biol Chem. 1996 Apr 5;271(14):8157-60.

40.

Novel self-association fibronectin sites.

Carnemolla B, Leprini A, Querzé G, Urbini S, Zardi L.

Biochem Cell Biol. 1996;74(6):745-8.

PMID:
9164644
41.

Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms.

Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stöcker G, et al.

Lab Invest. 1995 Aug;73(2):172-82.

PMID:
7543628
42.

Human tenascin gene. Structure of the 5'-region, identification, and characterization of the transcription regulatory sequences.

Gherzi R, Carnemolla B, Siri A, Ponassi M, Balza E, Zardi L.

J Biol Chem. 1995 Feb 17;270(7):3429-34.

43.

Cell-cycle dependent alternative splicing of the tenascin primary transcript.

Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querzé G, Zardi L.

Cell Adhes Commun. 1994 Jan;1(4):307-17.

PMID:
7521758
44.

Steady-state levels of different tenascin mRNAs in various normal human tissues.

Borsi L, Carnemolla B, Ponassi M, Zardi L.

Cell Biol Int. 1993 Mar;17(3):325-9.

PMID:
7685649
45.

The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence.

Carnemolla B, Leprini A, Allemanni G, Saginati M, Zardi L.

J Biol Chem. 1992 Dec 5;267(34):24689-92. Erratum in: J Biol Chem 1993 Apr 5;268(10):7602.

46.

Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues.

Borsi L, Carnemolla B, Nicolò G, Spina B, Tanara G, Zardi L.

Int J Cancer. 1992 Nov 11;52(5):688-92.

PMID:
1385335
47.

Comparison of human tenascin expression in normal, simian-virus-40-transformed and tumor-derived cell lines.

Carnemolla B, Borsi L, Bannikov G, Troyanovsky S, Zardi L.

Eur J Biochem. 1992 Apr 15;205(2):561-7.

48.

Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Siri A, Carnemolla B, Saginati M, Leprini A, Casari G, Baralle F, Zardi L.

Nucleic Acids Res. 1991 Feb 11;19(3):525-31.

49.

A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.

Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG.

J Cell Biol. 1989 Mar;108(3):1139-48.

50.

Modulation of matrix adhesive responses of human neuroblastoma cells by neighboring sequences in the fibronectins.

Mugnai G, Lewandowska K, Carnemolla B, Zardi L, Culp LA.

J Cell Biol. 1988 Mar;106(3):931-43.

Supplemental Content

Loading ...
Support Center